Dovitinib (lactate hydrate)

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively[1].

Product Specifications

CAS Number

[915769-50-5]

Product Name Alternative

TKI258 (lactate hydrate) ; CHIR-258 (lactate hydrate)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

C-Kit; FGFR; FLT3; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dovitinib-lactate-hydrate.html

Solubility

10 mM in DMSO

Smiles

O=C1NC2=C(C(F)=CC=C2)C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3.CC(O)C(O)=O.[H]O[H]

Molecular Formula

C24H29FN6O5

Molecular Weight

500.52

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Trudel S, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t (4;14) multiple myeloma. Blood. 2005, 105 (7), 2941-2948.